These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38510246)

  • 1. Precursor exhausted CD8
    Huang H; Ge J; Fang Z; Wu S; Jiang H; Lang Y; Chen J; Xiao W; Xu B; Liu Y; Chen L; Zheng X; Jiang J
    Front Immunol; 2024; 15():1362140. PubMed ID: 38510246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation.
    Lee J; Lee K; Bae H; Lee K; Lee S; Ma J; Jo K; Kim I; Jee B; Kang M; Im SJ
    Front Immunol; 2023; 14():1117092. PubMed ID: 37409128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revolutionizing tumor immunotherapy: unleashing the power of progenitor exhausted T cells.
    Fang Z; Ding X; Huang H; Jiang H; Jiang J; Zheng X
    Cancer Biol Med; 2024 May; 21(6):499-512. PubMed ID: 38825813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches.
    Dähling S; Mansilla AM; Knöpper K; Grafen A; Utzschneider DT; Ugur M; Whitney PG; Bachem A; Arampatzi P; Imdahl F; Kaisho T; Zehn D; Klauschen F; Garbi N; Kallies A; Saliba AE; Gasteiger G; Bedoui S; Kastenmüller W
    Immunity; 2022 Apr; 55(4):656-670.e8. PubMed ID: 35366396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
    Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NR4A1 transcriptionally regulates the differentiation of stem-like CD8
    Hao J; Li R; Zhao X; Liu X; Chen X; Xie T; Li X; Yao C; Sun Q; Wei K; Gou M; Chi X; Xu W; Ni L; Dong C
    Cell Rep; 2024 Jun; 43(6):114301. PubMed ID: 38823016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
    Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergism Between IL21 and Anti-PD-1 Combination Therapy is Underpinned by the Coordinated Reprogramming of the Immune Cellular Network in the Tumor Microenvironment.
    Wu S; Huang H; Sun R; Gao DS; Ye F; Huang J; Li E; Ni A; Lu KG; Chen K; Jiang J; Morel PA; Zhong Z; Lu B
    Cancer Res Commun; 2023 Aug; 3(8):1460-1472. PubMed ID: 37546701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-infiltrating gamma delta T-cells reveal exhausted subsets with remarkable heterogeneity in colorectal cancer.
    Yu L; Wang Z; Hu Y; Wang Y; Lu N; Zhang C
    Int J Cancer; 2023 Nov; 153(9):1684-1697. PubMed ID: 37531161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining an Alarmin HMGN1 Peptide with PD-L1 Blockade Results in Robust Antitumor Effects with a Concomitant Increase of Stem-Like/Progenitor Exhausted CD8
    Chen CY; Ueha S; Ishiwata Y; Shichino S; Yokochi S; Yang D; Oppenheim JJ; Ogiwara H; Deshimaru S; Kanno Y; Aoki H; Ogawa T; Shibayama S; Matsushima K
    Cancer Immunol Res; 2021 Oct; 9(10):1214-1228. PubMed ID: 34344641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells.
    Viramontes KM; Neubert EN; DeRogatis JM; Tinoco R
    Front Immunol; 2022; 13():869768. PubMed ID: 35774790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.
    Zheng Z; Wieder T; Mauerer B; Schäfer L; Kesselring R; Braumüller H
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained CD28 costimulation is required for self-renewal and differentiation of TCF-1
    Humblin E; Korpas I; Lu J; Filipescu D; van der Heide V; Goldstein S; Vaidya A; Soares-Schanoski A; Casati B; Selvan ME; Gümüş ZH; Wieland A; Corrado M; Cohen-Gould L; Bernstein E; Homann D; Chipuk J; Kamphorst AO
    Sci Immunol; 2023 Aug; 8(86):eadg0878. PubMed ID: 37624910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precursor exhausted T cells: key to successful immunotherapy?
    Kallies A; Zehn D; Utzschneider DT
    Nat Rev Immunol; 2020 Feb; 20(2):128-136. PubMed ID: 31591533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CD43 optimizes cancer immunotherapy through reinvigorating antitumor immune response in colorectal cancer.
    Li YY; Wang XY; Li Y; Wang XM; Liao J; Wang YZ; Hong H; Yi W; Chen J
    Cell Oncol (Dordr); 2023 Jun; 46(3):777-791. PubMed ID: 36920728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High HPK1
    Zhang J; Ren Z; Hu Y; Shang S; Wang R; Ma J; Zhang Z; Wu M; Wang F; Yu J; Chen D
    Int Immunopharmacol; 2024 Jan; 127():111363. PubMed ID: 38101218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
    Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.